Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.
In this study we show that cytarabine given simultaneously with 5-aza-2'-deoxycytidine (Aza-dC) antagonized Aza-dC activity against L1210 mouse leukemia. This antagonism was seen after a single dose (on Day 3 or Day 5 after tumor implant) and after repeated doses. This observation suggests caution in combining cytarabine with Aza-dC in the treatment of human leukemias.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D003561:Cytarabine / Q000008:administration & dosage; D000077209:Decitabine; D004347:Drug Interactions; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D013223:Statistics as Topic
D003561:Cytarabine; D000077209:Decitabine; D001374:Azacitidine